Efficacy and Safety of Shexiang Baoxin Pill for Coronary Heart Disease after Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis

OBJECTIVE: Shexiang Baoxin Pill (SBP) is a licensed Chinese herbal pharmaceutical that has been widely accustomed to treat coronary heart disease (CHD) after percutaneous coronary intervention (PCI). This study points to systematically assess the efficacy and security of the combination of SBP with...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jingjing, Liu, Shanshan, Wang, Xinlu, Li, Bin, Qiao, Lijie, Wang, Yongxia, Zhu, Mingjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684521/
https://www.ncbi.nlm.nih.gov/pubmed/34931125
http://dx.doi.org/10.1155/2021/2672516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684521/
https://www.ncbi.nlm.nih.gov/pubmed/34931125
http://dx.doi.org/10.1155/2021/2672516

Ejemplares similares